Biotech

Proteomics International Laboratories Ltd (ASX:PIQ) Study Validates Biomarkers for Endometriosis Blood Test

🕔2/1/2024 9:41:14 AM

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for endometriosis, PromarkerEndo, with the clinical validation of the biomarker panel in an independent patient group.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Study Validates Biomarkers for Oesophageal Cancer Blood Test

🕔2/1/2024 9:40:49 AM

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for oesophageal adenocarcinoma, PromarkerEso, with the clinical validation of the biomarker panel in a second independent patient group.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) To Raise $6.5m Through Institutional Placement

🕔1/23/2024 9:15:41 AM

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce that it has received firm commitments from new and existing institutional investors for a non-underwritten placement of 8.6 million new fully paid ordinary shares.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) December 2023 Quarterly Activities Report

🕔1/23/2024 8:57:11 AM

Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 31 December 2023 and subsequent to the period end.

Read Full Article

VGI Health Technology Limited (NSX:VTL) HREC Approval for Phase II Clinical Study

🕔1/11/2024 9:04:00 AM

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has received human ethics approval from the Human Research Ethics Committee of The Peter MacCallum Cancer Centre for its Phase II clinical study in Pancreatic Cancer.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerD Licence with Omics Global Extended to Chile

🕔12/20/2023 9:12:03 AM

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce the signing of a licence agreement to expand PromarkerD's reach in Central and South America.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) AGM Chairman's Address and Investor Presentation

🕔11/23/2023 12:22:57 PM

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the Chairman's Address provided by Mr Neville Gardiner and the Investor Presentation provided by Dr Richard Lipscombe to shareholders.

Read Full Article